Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Eric Horwitz

Email
Center AffiliationsMolecular Therapeutics

Publications (209) (print view)

paginate
Cahn DB, Handorf EA, Ghiraldi EM, Ristau BT, Geynisman DM, Churilla TM, Horwitz EM, Sobczak ML, Chen DY, Viterbo R, Greenberg RE, Kutikov A, Uzzo RG, Smaldone MC. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer. 2017 Jul 25;.
Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. The Canadian journal of urology. 2017 Feb;24(1):8656-62.
Dong Y, Zaorsky NG, Li T, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MA, Horwitz EM. Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. Journal of medical imaging and radiation oncology. 2017 Oct 13;.
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Mar 21;.
Jung K, Ghatalia P, Litwin S, Horwitz EM, Uzzo RG, Greenberg RE, Viterbo R, Geynisman DM, Kutikov A, Plimack ER, Smaldone MC, Wong YN, Bilusic M. Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clin Genitourin Cancer. 2017 Sep 30;15(3):e337-e343.
Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2017 May;71(5):766-73.
Lawton CA, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M, Kwok Y, Dignam JJ, Sandler HM. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Jun;98(2):296-303.   PMCID: PMC5603177
Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Journal of the National Cancer Institute. 2017 Feb;109(2):1-8.
Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Journal of the National Cancer Institute. 2017 Feb;109(2):1-8.
Shaikh T, Li T, Handorf EA, Johnson ME, Wang LS, Hallman MA, Greenberg RE, Price RA, Uzzo RG, Ma C, Chen D, Geynisman DM, Pollack A, Horwitz EM. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):722-31.   PMCID: PMC5331910
Shaikh T, Meyer JE, Horwitz EM. Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer. Surgical Oncology Clinics of North America. 2017 Jul;26(3):405-29.
Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, Md JM. Causes of death among cancer patients. Ann Oncol. 2017 Feb;28(2):400-7.
Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, Hoskin PJ, Yoshioka Y, Morton GC, Horwitz EM. The evolution of brachytherapy for prostate cancer. Nature reviews Urology. 2017 Jun 30;14(7):415-39.
Zaorsky NG, Shaikh T, Ruth K, Sharda P, Hayes SB, Sobczak ML, Hallman MA, Smaldone MC, Chen DY, Horwitz EM. Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy. Clin Genitourin Cancer. 2017 Apr;15(2):326-335 e3.
Avkshtol V, Dong Y, Hayes SB, Hallman MA, Price RA, Sobczak ML, Horwitz EM, Zaorsky NG. A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancer. Res Rep Urol. 2016 Jan;8:145-58.   PMCID: PMC4993397
Cahn DB, Ristau BT, Ghiraldi EM, Churilla TM, Geynisman DM, Horwitz EM, Uzzo RG, Smaldone MC. Bladder Preservation Therapy: A Review of the Literature and Future Directions. Urology. 2016 May 30;96:54-61.
Cahn DB, Ristau BT, Ghiraldi EM, Churilla TM, Geynisman DM, Horwitz EM, Uzzo RG, Smaldone MC. Bladder Preservation Therapy: A Review of the Literature and Future Directions. Urology. 2016 Oct;96:54-61.
Dong Y, Li T, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM. Effects of Time to Treatment on Biochemical and Clinical Outcomes for Patients With Prostate Cancer Treated With Definitive Radiation. Clin Genitourin Cancer. 2016 Oct;14(5):e463-e468.
Geynisman DM, Handorf E, Wong YN, Doyle J, Plimack ER, Horwitz EM, Canter DJ, Uzzo RG, Kutikov A, Smaldone MC. Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer medicine. 2016 Feb;5(2):192-9.   PMCID: 4735777
Johnson ME, Zaorsky NG, Martin JM, Ruth K, Greenberg RE, Uzzo RG, Hayes SB, Smaldone MC, Kutikov A, Viterbo R, Chen DY, Hallman MA, Sobczak ML, Horwitz EM. Patient reported outcomes among treatment modalities for prostate cancer. The Canadian journal of urology. 2016 Dec;23(6):8535-45.
Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol. 2016 Nov;121(2):294-8.
Kishan AU, Shaikh T, Wang J, Reiter R, Said J, Raghavan G, Nickols N, Aronson W, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Clinical Outcomes for Patients With Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiation Therapy or Radical Prostatectomy: A Comparative Analysis. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E229.
Meyer JE, Galloway TJ, Ruth K, Ross EA, Buyyounouski MK, Klayton TL, Hallman MA, Weiss SE, Hayes SB, Leahy J, Duncan G, Price RA, Horwitz EM, Ma CM. Efficacy of Pulsed Low-Dose-Rate Reirradiation: Results From a Phase 1 Clinical Trial. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):S147.
Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.
Shaikh T, Ruth K, Devarajan K, Zaorsky NG, Hallman MA, Sobczak ML, Chen D, Uzzo R, Smaldone MC, Kutikov A, Greenberg RE, Viterbo R, Pollack A, Horwitz EM. Dosimetric and Clinical Predictors of Long-Term Toxicity in Patients Undergoing Hypofractionated Prostate Radiation Therapy: Results From a Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2):S123.
Shaikh T, Wang L, Ruth K, Hallman M, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM. The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2016 Jan 29;15(2):156-62.   PMCID: PMC4789160
Uzzo RG, Horwitz EM, Plimack ER. Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. Future Oncol. 2016 Feb 17;12(7):887-91.
Veltchev I, Price R, Horwitz E, Ma C. SU-F-T-34: Transition Form CT-Based to Ultrasound-Based HDR Treatment Planning for Prostate Cancer. Med Phys. 2016 Jun;43(6):3469.
Veltchev I, Price R, Horwitz E, Ma C. SU-F-T-34: Transition Form CT-Based to Ultrasound-Based HDR Treatment Planning for Prostate Cancer. Med Phys. 2016 Jun;43(6):3469.
Zaorsky NG, Churilla TM, Ruth K, Hayes SB, Sobczak ML, Hallman MA, Smaldone MC, Chen DY, Horwitz EM. Men's health supplement use and outcomes in men receiving definitive intensity-modulated radiation therapy for localized prostate cancer. The American journal of clinical nutrition. 2016 Dec;104(6):1583-93.   PMCID: PMC5118729
Zaorsky NG, Egleston BL, Horwitz EM, Dicker AP, Nguyen PL, Showalter TN, Den RB. The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer. Am J Clin Oncol. 2016 Aug;39(4):321-6.
Zaorsky NG, Handorf E, Horwitz EM, Hallman MA, Smaldone MC. Pretreatment Predictors of Receiving Adjuvant Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 2016 Oct;96(2):E280.
Zaorsky NG, Keith SW, Shaikh T, Nguyen PL, Horwitz EM, Dicker AP, Den RB. Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. Am J Clin Oncol. 2016 Mar 24;.
Zaorsky NG, Ricco A, Churilla TM, Horwitz EM, Den RB. Applying ASTRO APEx Guidelines and RO-ILS to Medical Malpractice in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2):E540.
Zaorsky NG, Ricco AG, Churilla TM, Horwitz EM, Den RB. ASTRO APEx(R) and RO-ILS are applicable to medical malpractice in radiation oncology. Future Oncol. 2016 Nov;12(22):2643-57.
Zaorsky NG, Shaikh T, Handorf E, Eastwick G, Hesney A, Scher ED, Jones RT, Showalter TN, Avkshtol V, Rice SR, Horwitz EM, Meyer JE. What Are Medical Students in the United States Learning About Radiation Oncology? Results of a Multi-Institutional Survey. International Journal of Radiation Oncology Biology Physics. 2016 Feb;94(2):235-42.
Zaorsky NG, Shaikh T, Murphy CT, Hallman MA, Hayes SB, Sobczak ML, Horwitz EM. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treat Rev. 2016 Jun 17;48:50-60.
Huang KT, Stoyanova R, Walker G, Sandler K, Studenski MT, Dogan N, Al-Saleem T, Buyyounouski MK, Horwitz EM, Pollack A. Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. Radiother Oncol. 2015 Apr;115(1):101-6.   PMCID: 4922137
Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, Horwitz E, Malone S, Goldenberg L, Gospodarowicz M, Crook JM. Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT. J Clin Oncol. 2015 Apr;33(10):1151-6.
Martin JM, Handorf EA, Price RA, Cherian G, Buyyounouski MK, Chen DY, Kutikov A, Johnson ME, Ma CC, Horwitz EM. Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer. Medical Dosimetry. 2015 Jan;40(3):186-9.   PMCID: 4500753
Martin JM, Li T, Johnson ME, Murphy CT, Howald AG, Smaldone MC, Kutikov A, Chen DY, Viterbo R, Greenberg RE, Uzzo RG, Horwitz EM. Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center. J Natl Compr Canc Netw. 2015 May;13(5):525-30.
Murphy CT, Heller S, Ruth K, Buyyounouski MK, Weinberg D, Uzzo RG, Plimack E, Kutikov A, Chen DY, Horwitz EM. Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Practical radiation oncology. 2015 Jan;5(3):e215-e222.
Price R, Meyer J, Horwitz E, Ma C. SU-E-T-747: The Use of the EQD2 Formalism and Repair Estimates in the Re-Irradiation Setting and Correlation with Patient Follow-Up Data. Med Phys. 2015 Jun;42(6):3508.
Shaikh T, Handorf EA, Murphy CT, Kutikov A, Uzzo RG, Hallman M, Horwitz EM, Smaldone MC. Contemporary Trends in the Utilization of Radiotherapy in Patients With Renal Cell Carcinoma. Urology. 2015 Dec;86(6):1165-73.
Shaikh T, Zaorsky NG, Ruth K, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM. Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment. Brachytherapy. 2015 Jan;14(3):316-21.   PMCID: 4424094
Wang LS, Murphy CT, Ruth K, Zaorsky NG, Smaldone MC, Sobczak ML, Kutikov A, Viterbo R, Horwitz EM. Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2015 May 29;121(17):3010-7.   PMCID: 4545724
Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, Le QT, Gillison ML. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015 Jan 10;33(2):156-64.   PMCID: PMC4279235
Bagshaw H, Ruth K, Horwitz EM, Chen DY, Buyyounouski MK. Does family history of prostate cancer affect outcomes following radiotherapy?. Radiotherapy and Oncology. 2014 Feb;110(2):229-34.   PMCID: 3991234
Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer. 2014 Jul 15;120(14):2114-21.   PMCID: 4429530
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network. 2014 May;12(5):686-718.   PMCID: No NIH funding
Ahmed AA, Egleston B, Alcantara P, Li LN, Pollack A, Horwitz EM, Buyyounouski MK. A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for Age-Based Risk-Adapted Dose Constraints. International Journal of Radiation Oncology Biology Physics. 2013 Jul;86(4):709-15.   PMCID: PMC3860375
Johnson ME, Ruth K, Buyyounouski MK, Horwitz EM. Seminal Vesicle Target Delineation for Intermediate-Risk Prostate Cancer IMRT. Practical radiation oncology. 2013 Apr;3(2 Suppl 1):S31-2.   PMCID: Abstract
Li JS, Lin MH, Buyyounouski MK, Horwitz EM, Ma CM. Reduction of prostate intrafractional motion from shortening the treatment time. Physics in Medicine and Biology. 2013 Jul;58(14):4921-32.   PMCID: NIHMS 507153
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M. Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2013 Dec;11(12):1471-9.   PMCID: No NIH funding
Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, Stoyanova R, Movsas B, Greenberg RE, Uzzo RG, Ma C, Buyyounouski MK. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013 Nov;31(31):3860-8.   PMCID: PMC 3805927
Stoyanova R, Pahlajani NH, Egleston BL, Buyyounouski MK, Chen DY, Horwitz EM, Pollack A. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. Cancer. 2013 Mar;119(5):1080-8.
Townsend NC, Ruth K, Al-Saleem T, Horwitz EM, Sobczak M, Uzzo RG, Viterbo R, Buyyounouski MK. Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?. J Natl Compr Canc Netw. 2013 Jul;11(7):812-9.   PMCID: PMC3894783
Turaka A, Buyyounouski MK, Horwitz EM, Movsas B. In reply to cheung. Int J Radiat Oncol Biol Phys. 2013 May;86(1):6-7.   PMCID: Letter
Buyyounouski MK, Davis BJ, Prestidge BR, Shanahan TG, Stock RG, Grimm PD, Demanes DJ, Zaider M, Horwitz EM. A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. Brachytherapy. 2012 Jul;11(4):299-305.   PMCID: Not NIH funded
Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L. Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. The New England journal of medicine. 2012 Sep 06;367(10):895-903.   PMCID: PMC3521033 [Available on 2013/3/6]
Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012 Jan;11(1):6-19.   PMCID: not NIH funded
Horwitz EM. ABS brachytherapy consensus guidelines. Brachytherapy. 2012 Jan;11(1):4-5.
Keller LM, Buyyounouski MK, Sopka D, Ruth K, Klayton T, Pollack A, Watkins-Bruner D, Greenberg R, Price R, Horwitz EM. Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity-modulated Radiotherapy for Prostate Cancer. Urology. 2012 Aug;80(2):337-42.   PMCID: PMCID:PMC3461589[Available on 2013/8/1]
Klayton T, Price R, Buyyounouski MK, Sobczak M, Greenberg R, Li JS, Keller L, Sopka D, Kutikov A, Horwitz EM. Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment. International Journal of Radiation Oncology Biology Physics. 2012 Sep;84(1):130-6.   PMCID: PMC3285397
Lubbe W, Cohen R, Sharma N, Ruth K, Peters R, Li JS, Buyyounouski M, Kutikov A, Chen D, Uzzo R, Horwitz E. Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy. Brachytherapy. 2012 May;11(3):209-13.
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Sep;10(9):1081-7.   PMCID: Not NIH Funded
Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DY, Horwitz EM, Hanks GE, Price RA, Pollack A. RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON SCORE 8 TO 10 PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2012 Apr;82(5):1949-56.   PMCID: PMC3827957
Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. International Journal of Radiation Oncology Biology Physics. 2012 Mar;82(3):E433-E439.   PMCID: not NIH funded
Zaorsky NG, Buyyounouski MK, Li TY, Horwitz EM. Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation Therapy. International Journal of Radiation Oncology Biology Physics. 2012 Sep;84(1):E13-E17.   PMCID: PMC3423546
Zaorsky NG, Li TY, Devarajan K, Horwitz EM, Buyyounouski MK. Assessment of the American Joint Committee on Cancer Staging (Sixth and Seventh Editions) for Clinically Localized Prostate Cancer Treated With External Beam Radiotherapy and Comparison With the National Comprehensive Cancer Network Risk-Stratification Method. Cancer. 2012 Nov;118(22):5535-43.   PMCID: PMC3410044
Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer. Cancer. 2011 Jul;117(3):2883-91.   PMCID: PMC3139725
Canter D, Kutikov A, Horwitz EM, Greenberg RE. Transrectal implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. The Canadian journal of urology. 2011 Aug;18(4):5844-8.   PMCID: not NIH funded
Klayton TL, Ruth K, Buyyounouski MK, Uzzo RG, Wong YN, Chen DY, Sobczak M, Peter R, Horwitz EM. PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition. Practical radiation oncology. 2011 Jan;1(4):235-42.   PMCID: PMC3197783
Klayton TL, Ruth K, Horwitz EM, Uzzo RG, Kutikov A, Chen DY, Sobczak M, Buyyounouski MK. Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. Radiotherapy and Oncology. 2011 Dec;101(3):508-12.   PMCID: PMC3225561
Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, Goldsmith BJ, Horwitz EM, Ibbott GS, Lee WR, Nag S, Suh WW, Potters L. AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) AND AMERICAN COLLEGE OF RADIOLOGY (ACR) PRACTICE GUIDELINE FOR THE TRANSPERINEAL PERMANENT BRACHYTHERAPY OF PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Feb;79(2):335-41.   PMCID: PMCID: PMC3030655 [Available on 2012/2/1]
Sharma NK, Li TY, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):437-44.   PMCID: PMC2909627
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer. Int J Radiat Oncol Biol Phys. 2011 Jan;79(1):65-70.   PMCID: PMC3339153
Canter D, Greenberg RE, Horwitz EM, Kutikov A, Li J, Long C, Buyyounouski M, Boorjian SA. Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. The Canadian journal of urology. 2010 Oct;17(5):5365-9.   PMCID: not NIH funded
Chen LL, Paskalev K, Xu X, Zhu J, Wang L, Price RA, Hu W, Feigenberg SJ, Horwitz EM, Pollack A, Ma CM. Rectal dose variation during the course of image-guided radiation therapy of prostate cancer. Radiotherapy and Oncology. 2010 May;95(2):198-202.   PMCID: not NIH funded
Sharma NK, Cohen RJ, Eade TN, Buyyounouski MK, Uzzo RG, Li JS, Crawford K, Chen DY, McNeeley S, Horwitz EM. An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy. Brachytherapy. 2010 Apr;9(2):126-30.   PMCID: not NIH funded
Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiotherapy and Oncology. 2010 Jul;96(1):6-12.   PMCID: Not required
Turaka A, Li TY, Sharma NK, Li LN, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):599-603.   PMCID: not NIH funded
Li JS, Jin L, Pollack A, Horwitz EM, Buyyounouski MK, Price RA, Ma CM. Gains from real-time tracking of prostate motion during external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2009 Dec;75(5):1613-20.
Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, Horwitz EM. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2008 Jan;112(1):55-60.
Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Jan;70(1):59-66.
D'Ambrosio DJ, Ruth K, Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK. How Can Men Destined for Biochemical Failure After Androgen Deprivation and Radiotherapy Be Identified Earlier?. International Journal of Radiation Oncology, Biology, Physics. 2008 Jan;70(5):1487-91.
D'Ambrosio DJ, Li T, Horwitz EM, Chen DY, Pollack A, Buyyounouski MK. Does treatment duration affect outcome after radiotherapy for prostate cancer?. Int J Radiat Oncol Biol Phys. 2008 Dec;72(5):1402-7.
D'Ambrosio DJ, Ruth K, Horwitz EM, Chen DY, Pollack A, Buyyounouski MK. Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?. Urology. 2008 May;71(5):938-41.
Diefenbach M, Mohamed NE, Horwitz E, Pollack A. Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: the moderating role of age. Psychol Health Med. 2008 Mar;13(2):146-61.
Eade TN, Horwitz EM, Ruth K, Buyyounouski MK, D'Ambrosio DJ, Feigenberg SJ, Chen DY, Pollack A. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys. 2008 Jun;71(2):338-45.
Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504.
Horwitz EM, Feigenberg SJ, Pollack A. Intial management of high risk early stage prostate cancer: radiation. In: Kirby RS, editor. Treatment methods for early and advanced prostate cancer. London Boca Raton, FL: Informa Healthcare ; Distributed in North and South America by Taylor & Francis; 2008. p. 205-11.
Kaplan DJ, Crispen PL, Greenberg RE, Chen DY, Viterbo R, Buyyounouski MK, Horwitz EM, Uzzo RG. Residual prostate cancer after radiotherapy: a study of radical cystoprostatectomy specimens. Urology. 2008 Sep;72(3):654-8.   PMCID: PMC2660570
Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer. 2007 Jan;109(1):41-7.
Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. The Prostate. 2007 May;67(6):582-90.
D'Ambrosio DJ, Hanlon AL, Al-Saleem T, Feigenberg SJ, Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1082-7.
Eade TN, Al-Saleem T, Horwitz EM, Buyyounouski MK, Chen DY, Pollack A. Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. Cancer. 2007 May 15;109(10):2011-5.
Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys. 2007 Jul;68(3):682-9.
Feigenberg SJ, Paskalev K, McNeeley S, Horwitz EM, Konski A, Wang L, Ma C, Pollack A. Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluation. J Appl Clin Med Phys. 2007 Jan;8(3):2268.
Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007 Oct 20;25(30):4800-5.
Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer. 2007 Jul;110(1):68-80.
Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Radiation dose and late failures in prostate cancer. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1074-81.
Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. International Journal of Radiation Oncology Biology Physics. 2007 Feb;67(2):327-33.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer. American Journal of Clinical Oncology. 2006 Oct;29(5):458-62.
Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer. 2006 Aug 30;107(7):1496-502.
Konski A, Eisenberg D, Horwitz E, Hanlon A, Pollack A, Hanks G. Does age matter in the selection of treatment for men with early-stage prostate cancer?. Cancer. 2006 May 08;106(12):2598-602 .
Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, Horwitz EM, Pollack A. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Aug;66(2):408-15.
Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Aug;65(5):1487-93.
Langer CJ, Duffy K, Horwitz EM, Litwin S, Rosvold E, Schol J, Keenan E, Nicolaou N, Friedman CD, Ridge JA. Phase I Trial of Concurrent Hyperfractionated Split Course Radiotherapy (HFx RT), Cisplatin (cDDP), and Paclitaxel in Patients with Recurrent, Previously Irradiated, or Treatment-Naive Locally Advanced Upper Aerodigestive Malignancy. Cancer Invest. 2006 Jan;24(2):164-73.
Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma CM, McNeeley SW, Buyyounouski MK, Price RA. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Feb;64(2):518-26.
Price RA, Hannoun-Levi JM, Horwitz E, Buyyounouski M, Ruth KJ, Ma CM, Pollack A. Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Oct;66(2):583-92.
Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology. 2006 Dec;68(6):1257-62.
Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Mar;64(4):1140-50.
Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Increasing external beam dose for T1-T2 prostate cancer: Effect on risk groups. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Jul;65(4):975-81.
Uzzo RG, Crispen PL, Golovine K, Makhov P, Horwitz EM, Kolenko VM. Diverse effects of zinc on NF-{kappa}B and AP-1 transcription factors: implications for prostate cancer progression. Carcinogenesis. 2006 Oct;27(10):1980-90.
Andrews SF, Horwitz EM, Feigenberg SJ, Eisenberg DF, Hanlon AL, Uzzo RG, Pollack A. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?. Cancer. 2005 Jul 15;104(2):299-304.
Buyyounouski MK, Hanlon AL, Horwitz EM, Uzzo RG, Pollack A. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. International Journal of Radiation Oncology, Biology, Physics. 2005 Jan;61(5):1291-8.
Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2005 Dec;63(5):1455-62.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?. International Journal of Radiation Oncology Biology Physics. 2005 Mar 15;61(4):1003-10.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. International Journal of Radiation Oncology Biology Physics. 2005 Jun;62(2):397-405.
Horwitz EM. Does addition of 6 months' androgen suppression to radiotherapy prolong survival of men with prostate cancer?. Nature Clinical Practice Urology. 2005 Jan;2(1):16-7.
Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. Journal of Urology. 2005 Mar;173(3):797-802.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. International Journal of Radiation Oncology Biology Physics. 2005 Mar;61(3):695-701.
Kramer NM, Horwitz EM, Cheng J, Ridge JA, Feigenberg SJ, Cohen RB, Nicolaou N, Sherman EJ, Babb JS, Damsker JA, Langer CJ. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatln and paclitaxel chemotherapy from two prospective phase I and II studies. Head and Neck. 2005 Jan;27(5):406-14.
Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: Can one size fit all?. International Journal of Radiation Oncology Biology Physics. 2005 Feb;61(2):409-14.
Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. International Journal of Radiation Oncology Biology Physics. 2005 Feb;61(2):415-9.
Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. International Journal of Radiation Oncology Biology Physics. 2005 Nov;63(3):795-9.
Manne SL, Ostroff JS, Winkel G, Fox K, Grana G, Miller E, Ross S, Frazier T, Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A, Morrow M, Chen JQ, Yager JD, Russo J, Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ, Devlin J, Sherman E, Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR, Murphy ME, Langer CJ, Mehta MP, Viterbo R, Greenberg RE, Al-Saleem T, Canutescu AA, Dunbrack RL, Serebriiskii IG, Fang R, Latypova E, Hopkins R, Vinson C, Joung JK, Golemis EA. Couple-focused group intervention for women with early stage breast cancer. . J Consult Clin Psychol. 2005 Sep 15;73(4):634-46.
Paskalev K, Feigenberg S, Jacob R, McNeeley S, Horwitz E, Price R, Ma C, Pollack A. Target localization for post-prostatectomy patients using CT and ultrasound image guidance. Journal of Applied Clinical Medical Physics. 2005 Jan;6(4):40-9.
Pollack A, Price RA, Dong L, Feigenberg S, Horwitz E. Intact prostate cancer: case study. In: Mundte AJ, Roeske JC, editors. Intensity Modulated Radiation Therapy - A Clinical Perspective. Hamilton, ON: BC Decker Inc.; 2005. p. 459-63.
Pollack A, Price RA, Dong L, Feigenberg S, Horwitz E. Intact prostate cancer: overview. In: Mundte AJ, Roeske JC, editors. Intensity Modulated Radiation Therapy - A Clinical Perspective. Hamilton, ON: BC Decker Inc.; 2005. p. 336-448.
Ridge JA, Glisson BS, Horwitz E, Lango M. Head and Neck Cancer. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD, editors. Cancer Management: A Multidisciplinary Approach. Manhasset: CMP Healthcare Media; 2005. p. 43-90.
Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. Journal of Urology. 2005 Jan;173(5):1456-62.
Buyyounouski MK, Hanlon AL, Price RA, Horwitz EM, Feigenberg SJ, Pollack A. In regard to Selek et al. Erectile dysfunction and radiation dose to penile base structures: A lack of correlation (Int J Radiat Oncol Biol Phys) 2004;59 : 1039-1046. International Journal of Radiation Oncology Biology Physics. 2004 Dec;60(5):1664-5.
Buyyounouski MK, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A. Re: Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: Results from the search database - S.J. Freedland, J.C. Presti, Jr., M.K Terris, C.J. Kane, W.J. Aronson, F. Dorey and C.L. Amling for the SEARCH Database Study Group - J Urol, 169 : 2129-2135, 2003. Journal of Urology. 2004 Mar;171(3):1246-7.
Buyyounouski MK, Horwitz EM, Price RA, Hanlon AL, Uzzo RG, Pollack A. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2004 Mar;58(3):743-9.
Buyyounouski MK, Horwitz EM, Uzzo RG, Price RA, McNeeley SW, Azizi D, Hanlon AL, Milestone BN, Pollack A. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2004 Aug;59(5):1383-91.
Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. International Journal of Radiation Oncology Biology Physics. 2004 Jun;59(2):380-5.
Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E. Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. Journal of Clinical Oncology. 2004 Jul;22(14):2856-64.
Hanlon AL, Horwitz EM, Hanks GE, Pollack A. Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2004 Jan;58(1):43-52.
Horwitz EM, Feigenberg SJ, Pollack A, Hanks GE, Uzzo RG. Androgen suppression plus radiation therapy for prostate cancer. JAMA-Journal of the American Medical Association. 2004 Nov 03;292(17):2084-5.
Horwitz EM, Feigenberg SJ, Uzzo RG. The treatment of non-metastatic prostate cancer with external beam radiation therapy. Minerva Urologica e Nefrologica. 2004 Jun;56(2):173-88.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004 Feb;100(3):538-43.
Kramer NM, Horwitz EM, Uzzo RG, Hanlon AL, Hanks GE. Matched-cohort analysis of patients with prostate cancer followed with observation or treated with three-dimensional conformal radiation therapy. BJU international. 2004 Jul;94(1):59-62.
Manne S, Babb J, Pinover W, Horwitz E, Ebbert J. Psychoeducational group intervention for wives of men with prostate cancer. Psycho-Oncology. 2004 Jan;13(1):37-46.
Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: An update of the fox chase experience. Journal of Urology. 2004 Mar;171(3):1132-6.
Ridge JA, Glisson BS, Horwitz E, Meyers MO. Head and neck tumours. In: Pazur R, Coia LR, Hoskins WJ, Wagman LD, editors. Cancer Management: A Multidisciplinary Approach. Manhasset: CMP Healthcare Media; 2004. p. 39-85.
Uzzo RG, Brown JG, Horwitz EM, Hanlon A, Mazzoni S, Konski A, Greenberg RE, Pollack A, Kolenko V, Watkins-Bruner D. Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer. BJU international. 2004 May;93(7):955-60.
Uzzo RG, Cairns P, Dulin N, Horwitz EM, Pollack A, Kolenko V. Tumor resistance to apoptosis: Mechanisms of evasion and implications for radiation and chemotherapeutic strategies. Cancer Immunotherapy at the Crossroads. 2004 Jan;:215-34.
Buyyounouski MK, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE, Pollack A. Positive prostate biopsy laterality and implications for staging. Urology. 2003 Aug;62(2):298-303.
Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single vs. double high-risk factor stratification systems for prostate cancer treated radiotherapy without androgen deprivation. Int J Radiat Oncol Biol Phys. 2003 Oct;57(2 Suppl):S270.
Chism DB, Hanlon AL, Troncoso P, Al-Saleem T, Horwitz EM, Pollack A. The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys. 2003 Aug;56(5):1241-7.
Chism DB, Horwitz EM, Hanlon AL, Pinover WH, Mitra RK, Hanks GE. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys. 2003 Jan;55(1):71-7.
Diefenbach MA, Hamrick N, Uzzo R, Pollack A, Horwitz E, Greenberg R, Engstrom PF. Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. Journal of Urology. 2003 Jul;170(1):166-9.
Feigenberg SJ, Hanlon AL, Horwitz EM, Pollack A. Androgen deprivation increases late morbidity in prostate cancer patients treated with 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Oct;57(2 Suppl):S176.
Hammond E, Berkey BA, Fu KK, Trotti A, Meredith RF, Jones CU, Byhardt R, Horwitz EM, Ang KK, Radiation Therapy Oncology G. p105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: A clinical/laboratory correlative analysis of RTOG-9003. International Journal of Radiation Oncology Biology Physics. 2003 Nov;57(3):683-92.
Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. Journal of Clinical Oncology. 2003 Nov;21(21):3972-8.
Horwitz EM. Conformal radiotherapy with dose escalation appears safe and effective in localised prostate cancer. Cancer Treat Rev. 2003 Jun;29(3):219-21.
Horwitz EM, Mitra RK, Uzzo RG, Das IJ, Pinover WH, Hanlon AL, McNeeley SW, Hanks GE. Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants. Radiother Oncol. 2003 Feb;66(2):173-9.
Horwitz EM, Uzzo RG, Hanlon AL, Greenberg RE, Hanks GE, Pollack A. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. Journal of Urology. 2003 Jun;169(6):2153-7.
Horwitz EM, Uzzo RG, Miller N, Theodorescu D. Brachytherapy for prostate cancer follow-up and management of treatment failures. Urologic Clinics of North America. 2003 Nov;30(4):737--50, viii-ix.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with >15% risk of pelvic lymph-node involvement [meeting abstract]. Int J Radiat Oncol Biol Phys. 2003 Oct;57(2 Suppl):S150.
Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28.
Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003 Oct;57(2):391-401.
Nguyen KH, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?. Int J Radiat Oncol Biol Phys. 2003 Oct;57(2):377-83.
Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer. 2003 Feb 15;97(4):1127-33.
Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol. 2003 Sep;21(4):200-8.
Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Sep;57(1):19-23.
Pollack A, Horwitz EM, Movsas B. Treatment of prostate cancer with regional lymph node (N1) metastasis. Semin Radiat Oncol. 2003 Apr;13(2):121-9.
Pollack A, Horwitz EM, Movsas B, Hanlon AL. Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment. The Urologic clinics of North America. 2003 May;30(2):337-49.
Price RA, Murphy S, McNeeley SW, Charlie CM, Horwitz E, Movsas B, Raben A, Pollack A. A method for increased dose conformity and segment reduction for sMLC delivered IMRT treatment of the prostate. International Journal of Radiation Oncology Biology Physics. 2003 Nov;57(3):843-52.
Ridge JA, Glisson BS, Horwitz EM, Meyers M. Head and neck tumors. In: Ridge JA, Glisson BS, Horwitz EM, Meyers M, editors. Cancer management : a multidisciplinary approach : medical, surgical, & radiation oncology. New York: Oncology Group; 2003. p. 39-85.
Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):929-43.
Uzzo RG, Cairns P, Leavis P, Dulin N, Horwitz EM, Pollack A, Kolenko V. Tumor resistance to apoptosis: Mechanisms of evasion and implications for radiation and chemotherapeutic strategies. In: Finke JH, Bukowski RM, editors. Cancer immunotherapy at the crossroads : how tumors evade immunity and what can be done. Totowa, N.J.: Humana Press; 2003. p. 215-33.
Uzzo RG, Pinover WH, Horwitz EM, Parlanti A, Mazzoni S, Raysor S, Mirchandani I, Greenberg RE, Pollack A, Hanks GE, Watkins-Bruner D. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination. Urology. 2003 Apr;61(4):754-9.
Uzzo RG, Watkins-Bruner D, Horwitz EM, Konski A, Pollack A, Engstrom PF, Kolenko V. Prostate cancer prevention: strategies and realities. In: Mydlo JH, Godec CJ, editors. Prostate cancer : science and clinical practice. Amsterdam ; San Diego: Academic Press; 2003. p. 89-99.
Diefenbach MA, Dorsey J, Uzzo RG, Hanks GE, Greenberg RE, Horwitz E, Newton F, Engstrom PF. Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol. 2002 Feb;20(1):55-62.
Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys. 2002 Oct;54(2):427-35.
Kaminski JM, Hanlon AL, Horwitz EM, Pinover WH, Mitra RK, Hanks GE. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control. Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):888-92.
Kramer NM, Hanlon AL, Horwitz EM, Pinover WH, Hanks GH. Biochemical failure rates in prostate cancer patients predicted to have biologically insignificant tumors treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2002 Jun;53(2):277-81.
Mah D, Freedman G, Milestone B, Hanlon A, Palacio E, Richardson T, Movsas B, Mitra R, Horwitz E, Hanks GE. Measurement of intrafractional prostate motion using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002 Oct;54(2):568-75.
Mah D, Steckner M, Hanlon A, Freedman G, Milestone B, Mitra R, Shukla H, Movsas B, Horwitz E, Vaisanen PP, Hanks GE. MRI simulation: effect of gradient distortions on three-dimensional prostate cancer plans. Int J Radiat Oncol Biol Phys. 2002 Jul;53(3):757-65.
Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, Pollack A. Hypoxic prostate/muscle pO(2) ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology. 2002 Oct;60(4):634-9.
Pollack A, Horwitz EM. In regard to Sherertz et al., IJROBP 2001; 51:1241-1245 [letter]. Int J Radiat Oncol Biol Phys. 2002 Jun;53(2):512; author reply 512.
Price RA, Hanks GE, McNeeley SW, Horwitz EM, Pinover WH. Advantages of using noncoplanar vs. axial beam arrangements when treating prostate cancer with intensity-modulated radiation therapy and the step-and-shoot delivery method. Int J Radiat Oncol Biol Phys. 2002 May;53(1):236-43.
Ridge JA, Glisson BS, Horwitz EM, Meyers M, Fein DA, Watson JC. Head and neck tumors. In: Ridge JA, Glisson BS, Horwitz EM, Meyers M, editors. Cancer management : a multidisciplinary approach. Huntington, N.Y.: PRR; 2002. p. 37-78.
Hanks GE, Hanlon AL, Horwitz EM. Evidence for cure of 'young' men with prostate cancer. Oncology (Huntingt). 2001 May;15(5):563-7; discussion 571-4.
Hanlon AL, Pinover WH, Horwitz EM, Hanks GE. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):845-9.
Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001 Sep;92(5):1281-7.
Horwitz EM, Pinover WH, Hanks GE. Re: Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol. 2001 Apr;165(4):1224.
Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):947-56.
Mah D, Freedman G, Movsas B, Hanlon A, Mitra R, Horwitz E, Pinover W, Iyer R, Hanks GE. To move or not to move: measurements of prostate motion by urethrography using MRI. Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):947-51.
Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Pinover WH, Greenberg RE, Stobbe C, Hanks GE. Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. Am J Clin Oncol. 2001 Oct;24(5):458-61.
Anderson PR, Hanlon AL, Horwitz E, Pinover W, Hanks GE. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy. Cancer. 2000 Dec 15;89(12):2565-9.
Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys. 2000 Mar;46(4):823-32.
Horwitz EM, Hanks GE. Three-dimensional conformal radiation therapy: what are the costs and benefits?. Surg Oncol Clin N Am. 2000 Jul;9(3):455-67, viii.
Horwitz EM, Hanks GE. External beam radiation therapy for prostate cancer. CA: a cancer journal for clinicians. 2000 Nov;50(6):349-75; quiz 376-9.
Horwitz EM, Hanks GE. T3-T4NxM0: The case for radiotherapy. In: Resnick MI, Thompson IM, editors. Advanced therapy of prostate disease. Hamilton Ont. Lewiston, NY: B.C. Decker; 2000. p. 284-90.
Horwitz EM, Hanks GE. Hormonal therapy combined with radiation or surgery in treatment of locally advanced nonmetastatic prostate cancer. In: Vogelzang N, Scardino PT, Shipley WU, Coffey D, editors. Comprehensive textbook of genitourinary oncology. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 782-9.
Movsas B, Chapman JD, Greenberg RE, Hanlon AL, Horwitz EM, Pinover WH, Stobbe C, Hanks GE. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer. 2000 Nov;89(9):2018-24.
Pinover WH, Hanlon AL, Horwitz EM, Hanks GE. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer. Int J Radiat Oncol Biol Phys. 2000 Jun;47(3):649-54.
Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Schultheiss TE. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer Journal from Scientific American. 1999 May;5(3):152-8.
Horwitz EM, Hanlon AL, Pinover WH, Hanks GE. Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?. Radiation Oncology Investigations. 1999 Jan;7(4):249-59.
Horwitz EM, Hanlon AL, Pinover WH, Hanks GE. The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1999 Dec;45(5):1219-25.
Lattanzi J, McNeeley S, Pinover W, Horwitz E, Das I, Schultheiss TE, Hanks GE. A comparison of daily CT localization to a daily ultrasound- based system in prostate cancer. International Journal of Radiation Oncology Biology Physics. 1999 Mar;43(4):719-25.
Movsas B, Chapman JD, Horwitz EM, Pinover WH, Greenberg RE, Hanlon AL, Iyer R, Hanks GE. Hypoxic regions exist in human prostate carcinoma. Urology. 1999 Jan;53(1):11-8.
Horwitz EM, Hanlon AL, Hanks GE. Update on the treatment of prostate cancer with external beam irradiation. The Prostate. 1998 Nov;37(3):195-206.
Horwitz EM, Hanlon AL, Pinover WH, Hanks GE. The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy. International Journal of Radiation Oncology Biology Physics. 1998 Jun;41(3):519-23.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Eric Horwitz Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Thursday, November 02, 2017